ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Antihemophilic Factor (Recombinant) Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-6U6083
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Antihemophilic Factor Recombinant Market Size Status and Forecast 2021 2027
BUY CHAPTERS

Global Antihemophilic Factor (Recombinant) Market Research Report 2025

Code: QYRE-Auto-6U6083
Report
July 2025
Pages:78
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Takeda
Bayer
CSL Limited
Pfizer Inc
Biogen
Octapharma AG
Novo Nordisk
Sanofi
SOBI

Antihemophilic Factor (Recombinant) Market Size

The global market for Antihemophilic Factor (Recombinant) was valued at US$ 2358 million in the year 2024 and is projected to reach a revised size of US$ 3258 million by 2031, growing at a CAGR of 4.8% during the forecast period.

Antihemophilic Factor (Recombinant) Market

Antihemophilic Factor (Recombinant) Market

Antihemophilic factor is a naturally occurring protein in the blood that helps blood to clot.
The market for recombinant antihemophilic factor has witnessed significant growth in recent years. This can be attributed to several factors, including the increasing prevalence of hemophilia, advancements in recombinant DNA technology, and improved access to healthcare services. Hemophilia is a genetic bleeding disorder that requires lifelong treatment with antihemophilic factors, such as factor VIII or factor IX. Recombinant antihemophilic factor, produced using recombinant DNA technology, offers advantages over plasma-derived products, including enhanced safety, reduced risk of infection transmission, and increased supply stability.
This report aims to provide a comprehensive presentation of the global market for Antihemophilic Factor (Recombinant), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihemophilic Factor (Recombinant).
The Antihemophilic Factor (Recombinant) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antihemophilic Factor (Recombinant) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antihemophilic Factor (Recombinant) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Antihemophilic Factor (Recombinant) Market Report

Report Metric Details
Report Name Antihemophilic Factor (Recombinant) Market
Accounted market size in year US$ 2358 million
Forecasted market size in 2031 US$ 3258 million
CAGR 4.8%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • 200IU
  • 250IU
Segment by Application
  • Hospital
  • Clinic
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Takeda, Bayer, CSL, Pfizer, Biogen, Octapharma, Novo Nordisk, Sanofi, Sobi
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Antihemophilic Factor (Recombinant) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Antihemophilic Factor (Recombinant) Market growing?

Ans: The Antihemophilic Factor (Recombinant) Market witnessing a CAGR of 4.8% during the forecast period 2025-2031.

What is the Antihemophilic Factor (Recombinant) Market size in 2031?

Ans: The Antihemophilic Factor (Recombinant) Market size in 2031 will be US$ 3258 million.

Who are the main players in the Antihemophilic Factor (Recombinant) Market report?

Ans: The main players in the Antihemophilic Factor (Recombinant) Market are Takeda, Bayer, CSL, Pfizer, Biogen, Octapharma, Novo Nordisk, Sanofi, Sobi

What are the Application segmentation covered in the Antihemophilic Factor (Recombinant) Market report?

Ans: The Applications covered in the Antihemophilic Factor (Recombinant) Market report are Hospital, Clinic

What are the Type segmentation covered in the Antihemophilic Factor (Recombinant) Market report?

Ans: The Types covered in the Antihemophilic Factor (Recombinant) Market report are 200IU, 250IU

Recommended Reports

Coagulation Factor Markets

Recombinant Protein Drugs

Hemophilia and Clotting

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antihemophilic Factor (Recombinant) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 200IU
1.2.3 250IU
1.3 Market by Application
1.3.1 Global Antihemophilic Factor (Recombinant) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antihemophilic Factor (Recombinant) Market Perspective (2020-2031)
2.2 Global Antihemophilic Factor (Recombinant) Growth Trends by Region
2.2.1 Global Antihemophilic Factor (Recombinant) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Antihemophilic Factor (Recombinant) Historic Market Size by Region (2020-2025)
2.2.3 Antihemophilic Factor (Recombinant) Forecasted Market Size by Region (2026-2031)
2.3 Antihemophilic Factor (Recombinant) Market Dynamics
2.3.1 Antihemophilic Factor (Recombinant) Industry Trends
2.3.2 Antihemophilic Factor (Recombinant) Market Drivers
2.3.3 Antihemophilic Factor (Recombinant) Market Challenges
2.3.4 Antihemophilic Factor (Recombinant) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antihemophilic Factor (Recombinant) Players by Revenue
3.1.1 Global Top Antihemophilic Factor (Recombinant) Players by Revenue (2020-2025)
3.1.2 Global Antihemophilic Factor (Recombinant) Revenue Market Share by Players (2020-2025)
3.2 Global Antihemophilic Factor (Recombinant) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antihemophilic Factor (Recombinant) Revenue
3.4 Global Antihemophilic Factor (Recombinant) Market Concentration Ratio
3.4.1 Global Antihemophilic Factor (Recombinant) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antihemophilic Factor (Recombinant) Revenue in 2024
3.5 Global Key Players of Antihemophilic Factor (Recombinant) Head office and Area Served
3.6 Global Key Players of Antihemophilic Factor (Recombinant), Product and Application
3.7 Global Key Players of Antihemophilic Factor (Recombinant), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antihemophilic Factor (Recombinant) Breakdown Data by Type
4.1 Global Antihemophilic Factor (Recombinant) Historic Market Size by Type (2020-2025)
4.2 Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Type (2026-2031)
5 Antihemophilic Factor (Recombinant) Breakdown Data by Application
5.1 Global Antihemophilic Factor (Recombinant) Historic Market Size by Application (2020-2025)
5.2 Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Antihemophilic Factor (Recombinant) Market Size (2020-2031)
6.2 North America Antihemophilic Factor (Recombinant) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Antihemophilic Factor (Recombinant) Market Size by Country (2020-2025)
6.4 North America Antihemophilic Factor (Recombinant) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antihemophilic Factor (Recombinant) Market Size (2020-2031)
7.2 Europe Antihemophilic Factor (Recombinant) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Antihemophilic Factor (Recombinant) Market Size by Country (2020-2025)
7.4 Europe Antihemophilic Factor (Recombinant) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size (2020-2031)
8.2 Asia-Pacific Antihemophilic Factor (Recombinant) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region (2020-2025)
8.4 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antihemophilic Factor (Recombinant) Market Size (2020-2031)
9.2 Latin America Antihemophilic Factor (Recombinant) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Antihemophilic Factor (Recombinant) Market Size by Country (2020-2025)
9.4 Latin America Antihemophilic Factor (Recombinant) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size (2020-2031)
10.2 Middle East & Africa Antihemophilic Factor (Recombinant) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country (2020-2025)
10.4 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Takeda
11.1.1 Takeda Company Details
11.1.2 Takeda Business Overview
11.1.3 Takeda Antihemophilic Factor (Recombinant) Introduction
11.1.4 Takeda Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025)
11.1.5 Takeda Recent Development
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Bayer Business Overview
11.2.3 Bayer Antihemophilic Factor (Recombinant) Introduction
11.2.4 Bayer Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025)
11.2.5 Bayer Recent Development
11.3 CSL
11.3.1 CSL Company Details
11.3.2 CSL Business Overview
11.3.3 CSL Antihemophilic Factor (Recombinant) Introduction
11.3.4 CSL Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025)
11.3.5 CSL Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Antihemophilic Factor (Recombinant) Introduction
11.4.4 Pfizer Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025)
11.4.5 Pfizer Recent Development
11.5 Biogen
11.5.1 Biogen Company Details
11.5.2 Biogen Business Overview
11.5.3 Biogen Antihemophilic Factor (Recombinant) Introduction
11.5.4 Biogen Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025)
11.5.5 Biogen Recent Development
11.6 Octapharma
11.6.1 Octapharma Company Details
11.6.2 Octapharma Business Overview
11.6.3 Octapharma Antihemophilic Factor (Recombinant) Introduction
11.6.4 Octapharma Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025)
11.6.5 Octapharma Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Details
11.7.2 Novo Nordisk Business Overview
11.7.3 Novo Nordisk Antihemophilic Factor (Recombinant) Introduction
11.7.4 Novo Nordisk Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025)
11.7.5 Novo Nordisk Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Antihemophilic Factor (Recombinant) Introduction
11.8.4 Sanofi Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025)
11.8.5 Sanofi Recent Development
11.9 Sobi
11.9.1 Sobi Company Details
11.9.2 Sobi Business Overview
11.9.3 Sobi Antihemophilic Factor (Recombinant) Introduction
11.9.4 Sobi Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025)
11.9.5 Sobi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Takeda
Bayer
CSL Limited
Pfizer Inc
Biogen
Octapharma AG
Novo Nordisk
Sanofi
SOBI
List of Tables
 Table 1. Global Antihemophilic Factor (Recombinant) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of 200IU
 Table 3. Key Players of 250IU
 Table 4. Global Antihemophilic Factor (Recombinant) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Antihemophilic Factor (Recombinant) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Antihemophilic Factor (Recombinant) Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Antihemophilic Factor (Recombinant) Market Share by Region (2020-2025)
 Table 8. Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Antihemophilic Factor (Recombinant) Market Share by Region (2026-2031)
 Table 10. Antihemophilic Factor (Recombinant) Market Trends
 Table 11. Antihemophilic Factor (Recombinant) Market Drivers
 Table 12. Antihemophilic Factor (Recombinant) Market Challenges
 Table 13. Antihemophilic Factor (Recombinant) Market Restraints
 Table 14. Global Antihemophilic Factor (Recombinant) Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Antihemophilic Factor (Recombinant) Market Share by Players (2020-2025)
 Table 16. Global Top Antihemophilic Factor (Recombinant) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihemophilic Factor (Recombinant) as of 2024)
 Table 17. Ranking of Global Top Antihemophilic Factor (Recombinant) Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Antihemophilic Factor (Recombinant) Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Antihemophilic Factor (Recombinant), Headquarters and Area Served
 Table 20. Global Key Players of Antihemophilic Factor (Recombinant), Product and Application
 Table 21. Global Key Players of Antihemophilic Factor (Recombinant), Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Antihemophilic Factor (Recombinant) Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Type (2020-2025)
 Table 25. Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Type (2026-2031)
 Table 27. Global Antihemophilic Factor (Recombinant) Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Application (2020-2025)
 Table 29. Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Application (2026-2031)
 Table 31. North America Antihemophilic Factor (Recombinant) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Antihemophilic Factor (Recombinant) Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Antihemophilic Factor (Recombinant) Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Antihemophilic Factor (Recombinant) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Antihemophilic Factor (Recombinant) Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Antihemophilic Factor (Recombinant) Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Antihemophilic Factor (Recombinant) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Antihemophilic Factor (Recombinant) Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Antihemophilic Factor (Recombinant) Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Takeda Company Details
 Table 47. Takeda Business Overview
 Table 48. Takeda Antihemophilic Factor (Recombinant) Product
 Table 49. Takeda Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025) & (US$ Million)
 Table 50. Takeda Recent Development
 Table 51. Bayer Company Details
 Table 52. Bayer Business Overview
 Table 53. Bayer Antihemophilic Factor (Recombinant) Product
 Table 54. Bayer Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025) & (US$ Million)
 Table 55. Bayer Recent Development
 Table 56. CSL Company Details
 Table 57. CSL Business Overview
 Table 58. CSL Antihemophilic Factor (Recombinant) Product
 Table 59. CSL Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025) & (US$ Million)
 Table 60. CSL Recent Development
 Table 61. Pfizer Company Details
 Table 62. Pfizer Business Overview
 Table 63. Pfizer Antihemophilic Factor (Recombinant) Product
 Table 64. Pfizer Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025) & (US$ Million)
 Table 65. Pfizer Recent Development
 Table 66. Biogen Company Details
 Table 67. Biogen Business Overview
 Table 68. Biogen Antihemophilic Factor (Recombinant) Product
 Table 69. Biogen Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025) & (US$ Million)
 Table 70. Biogen Recent Development
 Table 71. Octapharma Company Details
 Table 72. Octapharma Business Overview
 Table 73. Octapharma Antihemophilic Factor (Recombinant) Product
 Table 74. Octapharma Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025) & (US$ Million)
 Table 75. Octapharma Recent Development
 Table 76. Novo Nordisk Company Details
 Table 77. Novo Nordisk Business Overview
 Table 78. Novo Nordisk Antihemophilic Factor (Recombinant) Product
 Table 79. Novo Nordisk Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025) & (US$ Million)
 Table 80. Novo Nordisk Recent Development
 Table 81. Sanofi Company Details
 Table 82. Sanofi Business Overview
 Table 83. Sanofi Antihemophilic Factor (Recombinant) Product
 Table 84. Sanofi Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025) & (US$ Million)
 Table 85. Sanofi Recent Development
 Table 86. Sobi Company Details
 Table 87. Sobi Business Overview
 Table 88. Sobi Antihemophilic Factor (Recombinant) Product
 Table 89. Sobi Revenue in Antihemophilic Factor (Recombinant) Business (2020-2025) & (US$ Million)
 Table 90. Sobi Recent Development
 Table 91. Research Programs/Design for This Report
 Table 92. Key Data Information from Secondary Sources
 Table 93. Key Data Information from Primary Sources
 Table 94. Authors List of This Report


List of Figures
 Figure 1. Antihemophilic Factor (Recombinant) Picture
 Figure 2. Global Antihemophilic Factor (Recombinant) Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Antihemophilic Factor (Recombinant) Market Share by Type: 2024 VS 2031
 Figure 4. 200IU Features
 Figure 5. 250IU Features
 Figure 6. Global Antihemophilic Factor (Recombinant) Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Antihemophilic Factor (Recombinant) Market Share by Application: 2024 VS 2031
 Figure 8. Hospital Case Studies
 Figure 9. Clinic Case Studies
 Figure 10. Antihemophilic Factor (Recombinant) Report Years Considered
 Figure 11. Global Antihemophilic Factor (Recombinant) Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 12. Global Antihemophilic Factor (Recombinant) Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Antihemophilic Factor (Recombinant) Market Share by Region: 2024 VS 2031
 Figure 14. Global Antihemophilic Factor (Recombinant) Market Share by Players in 2024
 Figure 15. Global Top Antihemophilic Factor (Recombinant) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihemophilic Factor (Recombinant) as of 2024)
 Figure 16. The Top 10 and 5 Players Market Share by Antihemophilic Factor (Recombinant) Revenue in 2024
 Figure 17. North America Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 18. North America Antihemophilic Factor (Recombinant) Market Share by Country (2020-2031)
 Figure 19. United States Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. Canada Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Europe Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Antihemophilic Factor (Recombinant) Market Share by Country (2020-2031)
 Figure 23. Germany Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. France Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. U.K. Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Italy Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Russia Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Nordic Countries Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Antihemophilic Factor (Recombinant) Market Share by Region (2020-2031)
 Figure 31. China Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Japan Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. South Korea Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Southeast Asia Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. India Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Australia Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Latin America Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Antihemophilic Factor (Recombinant) Market Share by Country (2020-2031)
 Figure 39. Mexico Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Brazil Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Antihemophilic Factor (Recombinant) Market Share by Country (2020-2031)
 Figure 43. Turkey Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Saudi Arabia Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. UAE Antihemophilic Factor (Recombinant) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Takeda Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2020-2025)
 Figure 47. Bayer Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2020-2025)
 Figure 48. CSL Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2020-2025)
 Figure 49. Pfizer Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2020-2025)
 Figure 50. Biogen Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2020-2025)
 Figure 51. Octapharma Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2020-2025)
 Figure 52. Novo Nordisk Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2020-2025)
 Figure 53. Sanofi Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2020-2025)
 Figure 54. Sobi Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2020-2025)
 Figure 55. Bottom-up and Top-down Approaches for This Report
 Figure 56. Data Triangulation
 Figure 57. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Recombinant Antihemophilic Factor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antihemophilic Factor Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Recombinant Antihemophilic Globulin Market Research Report 2024
Recombinant Factor VIII Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Recombinant Coagulation Factor Concentrate Market Research Report 2024
Cryoprecipitated Antihemophilic Factor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Human Coagulation Factor Ⅷ Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Human Coagulation Factor VIII Market Research Report 2020
Rare Hemophilia Factors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antithrombin Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antihemophilic Factor von Willebrand Factor Complex Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Recombinant Coagulation Factor Ⅷ for Injection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Coagulation Factors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Coagulation Factor Concentrate Market Research Report 2025
Global Recombinant Activated Coagulation Factor VII Market Research Report 2025
Global Management of Antithrombin Market Research Report 2024
Global Clotting Factor Market Research Report 2025
Hemophilia Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Human Coagulation Factor VII Market Insights Forecast to 2030
Plasma derived Factor VIII Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions